开发嵌合蛋白作为人源动质体感染(恰加斯病和利什曼病)的多价疫苗
针对利什曼原虫属和克氏锥虫无疫苗可用,研究者选取两者保守的CD8+ T细胞表位构建多价广谱嵌合多蛋白疫苗;免疫小鼠后除诱导特异性IgG外,还显著降低克氏锥虫、婴儿利什曼原虫和墨西哥利什曼原虫攻击小鼠的寄生虫负荷,组织病理显示相应炎症减轻。
要点
- 选取利什曼原虫属和克氏锥虫保守的CD8+ T细胞表位构建嵌合多蛋白疫苗。
- 免疫可诱导特异性IgG并显著降低三种动质体攻击小鼠的寄生虫负荷。
- 组织病理显示结肠炎症减轻、肝细胞变性减少、皮肤病变结缔组织增生。
核心结论
- 结果支持多蛋白疫苗方法的保护效果,并作为单一多动质体疫苗可有效控制不同感染病因的概念性证明。
研究设计与样本
- 选取利什曼原虫属和克氏锥虫保守的CD8+ T细胞表位构建多价广谱嵌合多蛋白疫苗,并在克氏锥虫、婴儿利什曼原虫和墨西哥利什曼原虫攻击的小鼠中评估。
主要发现
- 免疫除诱导特异性IgG产生外,还显著降低克氏锥虫攻击小鼠结肠、婴儿利什曼原虫攻击小鼠肝脏和墨西哥利什曼原虫攻击小鼠皮肤病变中的寄生虫负荷。
局限性
- 原文指出需进一步研究以阐明与保护相关的免疫特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Leishmania spp. and Trypanosoma cruzi are parasitic kinetoplastids of great medical and epidemiological importance since they are responsible for thousands of deaths and disability-adjusted life-years annually, especially in low- and middle-income countries. Despite efforts to minimize their impact, current prevention measures have failed to fully control their spread. There are still no vaccines available. Taking into account the genetic similarity within the Class Kinetoplastida, we selected CD8+ T cell epitopes preserved among Leishmania spp. and T. cruzi to construct a multivalent and broad-spectrum chimeric polyprotein vaccine. In addition to inducing specific IgG production, immunization with the vaccine was able to significantly reduce parasite burden in the colon, liver and skin lesions from T. cruzi, L. infantum and L. mexicana challenged mice, respectively. These findings were supported by histopathological analysis, which revealed decreased inflammation in the colon, a reduced number of degenerated hepatocytes and an increased proliferation of connective tissue in the skin lesions of the corresponding T. cruzi, L. infantum and L. mexicana vaccinated and challenged mice. Collectively, our results support the protective effect of a polyprotein vaccine approach and further studies will elucidate the immune profile associated with this protection. Noteworthy, our results act as conceptual proof that a single multi-kinetoplastida vaccine can be used effectively to control different infectious etiologies, which in turn can have a profound impact on the development of a new generation of vaccines.
引用
- Clímaco MC, de Figueiredo LA, Lucas RC, et al. Development of chimeric protein as a multivalent vaccine for human Kinetoplastid infections: Chagas disease and leishmaniasis. Vaccine. 2023. PMID: 37479612. doi:10.1016/j.vaccine.2023.07.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。